NasdaqGS:STOKBiotechs
How Accelerated EMPEROR Enrollment and Expedited FDA Talks At Stoke Therapeutics (STOK) Have Changed Its Investment Story
Earlier in January 2026, Stoke Therapeutics announced accelerated timelines for completing enrollment in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with enrollment now expected to finish in the second quarter of 2026 and a Phase 3 data readout anticipated in mid-2027 to support a rolling NDA submission.
An important insight is the ongoing multidisciplinary dialogue with the FDA under Breakthrough Therapy Designation, which highlights active exploration of expedited...